Meet the Interventional Oncology External Innovation team
We are seeking external innovations to further our intratumoral portfolio.
-
Ann Ballesteros, Ph.D.
Director, Alliance Management, Interventional Oncology
-
Kai Stoeber, Ph.D.
External Innovation Lead, EMEA, Interventional Oncology
Key areas of interest
At Interventional Oncology, we believe developing new intratumoral and local therapies will help transform the standard of care for cancer patients. Our areas of interest include:
Cytotoxic agents
Drugs with enhanced cytotoxic activity and drug depot technologies/controlled release platforms
Immune activating agents
Pro-inflammatory cytokines and energy-based modalities that activate the immune system.
Therapies that potentiate the effects of radiation
Locally delivered or activated agents, and systemically delivered therapies that enhance local radiation therapy
Platforms
Drug delivery platforms for small molecules, nucleic acid delivery and protein delivery
Procedure enablers
Technologies used to plan, deliver, monitor, and confirm IT therapy delivery, as well as new models for local delivery
Emerging and transformational intratumoral approaches
Emerging technologies
We are seeking external innovations to further our intratumoral portfolio. Contact us for partnership opporunities.